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OBJECTIVE — Tocompareextra-lipideffectsofstatinsandﬁbratesinrelationtothebaseline
metabolic status of patients.
RESEARCHDESIGNANDMETHODS — Thestudyinvolvedagroupof242metabolic
syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenoﬁbrate, or
placebo.
RESULTS — Compared with matched healthy subjects, metabolic syndrome patients exhib-
ited higher plasma levels/activities of high-sensitivity C-reactive protein (hs-CRP), ﬁbrinogen,
factor VII, plasminogen activator inhibitor 1, and enhanced monocyte cytokine release. These
abnormalities were alleviated by both atorvastatin and fenoﬁbrate treatment. CRP-lowering and
monocyte-suppressingactionsweremorepronouncedforatorvastatininsubjectswithimpaired
fasting glucose and for fenoﬁbrate in patients with impaired glucose tolerance.
CONCLUSIONS — The presence of pre-diabetes potentiates metabolic syndrome–induced
abnormalities in plasma markers of inﬂammation and hemostasis and in monocyte secretory
function.Bothatorvastatinandfenoﬁbrateexhibitmultidirectionalpleiotropiceffectsinsubjects
with metabolic syndrome, the strength of which seem to be partially determined by the type of
pre-diabetes.
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T
he anti-inﬂammatory, endothelial-
protective, antioxidant, and anti-
thrombotic actions of statins and
ﬁbrates are observed not only in pa-
tients with dyslipidemia (1–5) but also
in subjects with early and late glucose
metabolism abnormalities (6–8). This
suggests that metabolic syndrome (MS)
patients may receive more beneﬁts from
statin or ﬁbrate treatment than individ-
uals suffering from isolated lipid or glu-
cose metabolism disturbances. No
previous study has examined whether
the presence and type of pre-diabetes
determines cardiovascular risk factor
concentrations and the extra-lipid ef-
fects of lipid-lowering agents in MS
patients.
RESEARCH DESIGN AND
METHODS— The study included
242 patients with recently diagnosed
and previously untreated MS. MS was
diagnosed using National Cholesterol
Education Program Adult Treatment
Panel III criteria. The exclusion criteria
and power calculations are described in
the online appendix (available at http://
care.diabetesjournals.org/cgi/content/
full/dc10-0272/DC1). The study pro-
tocol was approved by the local ethics
committee. All enrolled MS patients
were given detailed advice on how to
achieve the goals of lifestyle modiﬁca-
tion: a reduction in weight of 7% or
more if necessary; total fat intake less
than 30% of total energy intake; satu-
rated fat intake less than 7% of energy
consumed; cholesterol intake less than
200-mg per day; an increase in ﬁber in-
take to 15-g per 1,000 kcal; and mod-
erate-to-vigorous exercise for at least 30
min per day. On the basis of fasting
plasma glucose, MS patients were allo-
cated into one of the two groups: pa-
tients with pre-diabetes (n  183) and
patients with normal glucose tolerance
(NGT) (n  59) (online appendix). The
former group was additionally divided
into three subgroups: patients with iso-
lated fasting glucose (IFG) (n  61),
patients with isolated impaired glucose
tolerance (IGT) (n  62), and patients
with concomitant IFG and IGT (IFG 
IGT) (n  60). The patients in each
group were randomized in a double-
blind fashion to micronized fenoﬁbrate
(200 mg), atorvastatin (40 mg), or pla-
cebo, which were administered once
daily for 90 days. MS patients were
compared with age- and sex-matched
healthy subjects without lipid and glu-
cose metabolism abnormalities (n 
48). Plasma lipid/lipoprotein proﬁle,
total free fatty acids, fasting and 2-h
postchallenge glucose levels, A1C, ho-
meostasis model assessment (HOMA)
index, high-sensitivity C-reactive pro-
tein (hs-CRP), ﬁbrinogen, factor VII,
plasminogen activator inhibitor 1 (PAI-
1), and monocyte production of tumor
necrosis factor-, interleukin (IL)-1,
IL-6, and monocyte chemoattractant
protein-1 were determined before and
after 30 and 90 days of therapy (4,6,9).
Statistical analysis was performed as
previously described (4,6).
RESULTS— Apart from disturbances
in lipid proﬁle and glucose metabolism
markers, the presence of MS was associ-
ated with higher plasma levels/activity of
hs-CRP,ﬁbrinogen,factorVII,andPAI-1,
and increased monocyte release of tumor
necrosis factor-, IL-1, IL-6, and mono-
cyte chemoattractant protein-1 (online
appendix Table 1). No serious adverse ef-
fectswereobservedthroughoutthestudy,
and 234 patients completed the study
(online appendix).
In pre-diabetic patients, only feno-
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Atorvastatin and fenoﬁbrate in metabolic syndrome
2268 DIABETES CARE, VOLUME 33, NUMBER 10, OCTOBER 2010 care.diabetesjournals.orgﬁbrate decreased fasting and postchal-
lenge plasma glucose, HOMA index,
and A1C (Table 1). In MS patients with
NGT or pre-diabetes, atorvastatin and
fenoﬁbrate improved lipid/lipoprotein
proﬁle, reduced monocyte cytokine re-
lease, and decreased plasma levels/
activity of hs-CRP, factor VII, and
PAI-1. Fenoﬁbrate also decreased
plasma ﬁbrinogen. In MS patients with
eitherpre-diabetesorNGT,atorvastatin
stronger than fenoﬁbrate reduced
plasma levels of total and LDL choles-
terol, apoprotein B, oxidized LDLs, and
PAI-1, while fenoﬁbrate to a greater ex-
tent than atorvastatin affected triglycer-
ides, apoprotein A-I, and ﬁbrinogen. In
MS patients with NGT and, when ana-
lyzed together, also in MS patients with
pre-diabetes, both drugs were equipo-
tent in their effect on plasma hs-CRP
and monocyte cytokine release.
Fenoﬁbrate was superior to atorva-
statin in reducing fasting and postglu-
cose load plasma glucose in IGT and
IFG  IGT patients, as well as in reduc-
ing HOMA index and A1C in all sub-
groups of pre-diabetic patients (online
appendix Table 2). Fenoﬁbrate more
markedly decreased fasting plasma glu-
cose in IFG  IGT patients than in the
remaining groups of pre-diabetic sub-
jects.Atorvastatinactiononhs-CRPand
monocyte cytokine release was stronger
in IFG and IFG IGT patients than in
IGT patients. In turn, fenoﬁbrate action
on these markers was more pronounced
in IGT and IFG  IGT patients than in
IFG patients. In IFG subjects, atorvasta-
tin stronger than fenoﬁbrate reduced
plasma hs-CRP and monocyte cytokine
release, whereas the opposite relation-
ship was found in IGT patients. In
IFG  IGT subjects, the effect of both
drugs on hs-CRP and cytokine release
was similar to each other, and their
post-treatment values remained higher
than in control subjects. The atorvasta-
tin- or fenoﬁbrate-induced reduction in
IL-1 release reached the highest de-
gree in patients with concomitant IFG
and IGT. Correlations are presented in
the online appendix Supplemental
Results.
CONCLUSIONS — This prospec-
tive, randomized, placebo-controlled
study has shown that cytokine release,
low-grade inﬂammation, coagulation,
and ﬁbrinolysis were more profoundly
disturbed in pre-diabetic patients, par-
ticularly in those with concomitant
presence of IFG and IGT than in MS
subjects with NGT. Considering that
the assessed variables are proven vascu-
lar risk factors (2,10–12), the obtained
results suggest the earlier development
and faster progression of cardiovascular
and cerebrovascular disorders if MS is
accompanied by pre-diabetes and par-
tially explain the differences in the clin-
ical course between IFG and IGT (13–
15). Coexistence of both pre-diabetic
conditionsseemstobeassociatedwitha
greater cardiovascular and cerebrovas-
cular risk than the presence of only one
of them.
The study has documented the supe-
riority of the ﬁbrate over the statin treat-
ment in inﬂuencing glucose homeostasis
and has revealed that fenoﬁbrate action
on glycemic control was pre-diabetes–
type dependent. This indicates that only
ﬁbrates may delay the development of di-
abetes in MS patients, particularly in in-
dividuals with either isolated IGT or with
coexisting IFG and IGT.
The magnitude of the reduction in
monocyte cytokine release and plasma
levels/activities of factor VII and hs-CRP
was similar for both agents. Although fe-
noﬁbrate was superior to atorvastatin in
reducing ﬁbrinogen, the latter drug more
markedly decreased PAI-1. These results
indicate that both ﬁbrates and statins
effectively reduce vascular risk in MS
patients. Although the global anti-
inﬂammatory and monocyte-suppressing
effect was similar in magnitude for ator-
vastatin and fenoﬁbrate in the entire pop-
ulation of pre-diabetic patients, the
strength of this action depended on the
patients’ metabolic proﬁles. This ﬁnding
suggests that IGT patients may beneﬁt
morefromﬁbratetreatment,whereasIFG
subjects may be better candidates for sta-
tin therapy.
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